<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04827719</url>
  </required_header>
  <id_info>
    <org_study_id>GFM-BST003</org_study_id>
    <nct_id>NCT04827719</nct_id>
  </id_info>
  <brief_title>BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS</brief_title>
  <official_title>Phase 2, Open-Label, Single Arm, Multi-Center Study to Assess the Efficacy and Safety of BST-236 as a Single Agent in Adults Unfit for Intensive Chemotherapy With Relapsed or Refractory Acute Myeloid Leukemia or HR-MDS .</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Francophone des Myelodysplasies</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Groupe Francophone des Myelodysplasies</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the efficacy, and safety of BST-236 in patients unfit for intensive chemotherapy&#xD;
      with AML or HR MDS that failed or relapsed following first line therapy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, phase 2, open-label, multi-center, single arm, single agent study, in&#xD;
      unfit adult patients with AML or HR MDS who failed or relapsed following first-line therapy.&#xD;
&#xD;
      The study consists of three periods:&#xD;
&#xD;
      Screening: Up to 28 days Treatment: Recurrent 6 days treatment courses with BST-236&#xD;
      Follow-up: The period of time from last day of BST-236 treatment to completion of one year&#xD;
      (365 days ±7 days) from the first day of BST-236 treatment&#xD;
&#xD;
      Post-study Follow-up: The period of time from last day of BST-236 treatment to completion of&#xD;
      one year (365 days ±7 days) from the first day of BST-236 treatment&#xD;
&#xD;
      Follow-up: One-Year follow-up of survival, starting at the end of study visit&#xD;
&#xD;
      Treatment period: After signing the Informed Consent Form (ICF), meeting all eligibility&#xD;
      criteria, and undergoing screening assessments for up to four weeks, eligible patients will&#xD;
      receive the first induction course with BST-236, 4.5 g/m2/d administered IV over 1 hour for 6&#xD;
      consecutive days. The first day of the induction is defined as Study Day 1. Following the&#xD;
      first treatment course:&#xD;
&#xD;
        1. AML patients in complete remission (CR) or CR with incomplete count recovery (CRi) or CR&#xD;
           with partial hematologic recovery (CRh), and HR MDS patients with CR will receive&#xD;
           between 2 to 4 maintenance courses of 6-day treatment with BST-236, every 4-6 weeks. The&#xD;
           BST-236 dose in these subsequent treatment courses will be 2.3g /m2/d or 4.5 g/m2/d. The&#xD;
           reduced dose must be used in case of previous courses toxicity and is allowed in certain&#xD;
           cases according to physician discretion following consultation with the study medical&#xD;
           monitor. The interval between treatment courses may be extended to up to 12 weeks to&#xD;
           allow resolution of toxicities per investigator discretion and in consultation with&#xD;
           principal investigators.&#xD;
&#xD;
        2. Patients with stable disease defined as failure to achieve at least PR, but with no&#xD;
           evidence of disease progression or patients in partial response (PR) will receive a&#xD;
           second 6-day course with BST-236, at a dose of 4.5 g/m2/d. Following which:&#xD;
&#xD;
             1. AML patients in PR or CR, (including CR, CRh or CRi) and HR MDS patients in PR or&#xD;
                CR will be treated with maintenance courses as detailed above Patients in stable&#xD;
                disease or disease progression may receive alternative treatment outside of the&#xD;
                protocol and will be followed for overall survival (OS) until the completion of 1&#xD;
                year of participation in the study (365 days±7 days from the first day of BST-236&#xD;
                treatment). Additional 1 year of post study follow-up will be implemented for these&#xD;
                patients in order to follow up on their survival status and their current AML/MDS&#xD;
                treatments.&#xD;
&#xD;
      Patients that have a disease progression while treated in the maintenance courses, will not&#xD;
      receive any additional BST-236 treatment and will be followed until the completion of 1 year&#xD;
      of participation in the study. These patients may also receive alternative treatment outside&#xD;
      of the protocol, in such case, they will be followed in regular intervals for progression&#xD;
      free survival, OS and development of new malignancies.&#xD;
&#xD;
      Follow-up period: All patients will be followed by periodic in person in-clinic visits, until&#xD;
      the completion of 1 year of participation in the study (365 days±7 days from the first&#xD;
      BST-236 treatment day).&#xD;
&#xD;
      End of Study (EOS) visits: will be performed on the last day of participation in the study&#xD;
      for all patients.&#xD;
&#xD;
      Scheduled in-clinic visits to assess safety and efficacy outcomes will be conducted during&#xD;
      the study periods as specified in the Schedule of Activities.&#xD;
&#xD;
      Unscheduled visits may be conducted at any time for safety reasons or for any other reason.&#xD;
&#xD;
      Post study follow-up: All patients will be followed for survival for an additional 1 year&#xD;
      from the EOS&#xD;
&#xD;
      QT Evaluation with Pharmacokinetics (PK) sub-study: Up to 20 patients participating in the&#xD;
      main study in pre-selected sites, will be asked to participate in a QT evaluation with PK&#xD;
      sub-study to assess the effect of BST-236 on the cardiac electrophysiology. In this study, up&#xD;
      to 14 blood samples for PK analysis will be taken from each patient during the first&#xD;
      induction course and a continuous electrocardiogram (ECG) recording by a Holter monitor will&#xD;
      be done in the first 24 hours of BST-236 administration. Patients participating in this study&#xD;
      will be asked to sign an additional ICF for the collection of the PK blood samples and ECG&#xD;
      recording.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2021</start_date>
  <completion_date type="Anticipated">April 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall hematological response</measure>
    <time_frame>2 months</time_frame>
    <description>Overall response rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>response duration</measure>
    <time_frame>12 months</time_frame>
    <description>response duration</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>BST-236</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recurrent 6 days treatment courses with BST-236 (4.5 g/m2/d administered IV over 1 hour for 6 consecutive days)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BST-236</intervention_name>
    <description>Recurrent 6 days treatment courses with BST-236 (4.5 g/m2/d administered IV over 1 hour for 6 consecutive days)</description>
    <arm_group_label>BST-236</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients must meet all of the following inclusion criteria to be eligible for enrollment&#xD;
        into the study:&#xD;
&#xD;
          1. Documented diagnosis of MDS, according to World Health Organization (WHO)&#xD;
             classification (Appendix 1) and assessed as higher risk MDS, prior to first line&#xD;
             hypomethylating agents (HMA) treatment, according to the Revised International&#xD;
             Prognostic Scoring System (IPSS-R) (IPSS-R overall score ≥ 4.5) Or Diagnosed AML&#xD;
             according to the 2016 revision to the WHO classification of myeloid neoplasms and&#xD;
             acute leukemia: ≥20% blasts in peripheral blood or bone marrow&#xD;
&#xD;
          2. Adult ≥18 years of age&#xD;
&#xD;
          3. Failure/relapse following prior first-line AML or MDS treatment, defined as:&#xD;
&#xD;
               1. For MDS:&#xD;
&#xD;
                    -  Relapse after initial complete or partial response or stable disease with&#xD;
                       hematologic improvement (HI), according to International Working Group (IWG)&#xD;
                       2006 criteria following treatment with azacitidine or decitabine Or&#xD;
&#xD;
                    -  Failure to achieve complete or partial response or stable disease with&#xD;
                       hematologic improvement (HI) according to International Working Group (IWG)&#xD;
                       2006 criteria after at least 4 cycles of azacitidine or decitabine, all&#xD;
                       within the last 1 year Or iii. MDS progression while on azacitidine or&#xD;
                       decitabine treatment irrespective of the number of cycles the patient has&#xD;
                       received&#xD;
&#xD;
               2. For AML:&#xD;
&#xD;
                    -  Relapse after initial CR/CRi/CRh following treatment with: azacitidine,&#xD;
                       decitabine, Low-Dose Ara-C (cytarabine) [LDAC] (20 mg/m2/d), venetoclax+HMA,&#xD;
                       or venetoclax+LDAC Or&#xD;
&#xD;
                    -  Failure to achieve CR, CRh or CRi following at least 4 cycles of azacitidine&#xD;
                       or decitabine or 2 cycles of venetoclax+HMA or venetoclax+LDAC within the&#xD;
                       last 1 year.&#xD;
&#xD;
             Or&#xD;
&#xD;
             - AML progression while on azacitidine, decitabine, LDAC, venetoclax+HMA,&#xD;
             venetoclax+LDAC, irrespective of the number of cycles the patient has received.&#xD;
&#xD;
          4. The participant is not able to receive an allogeneic bone marrow transplantation (BMT)&#xD;
             at the time of study enrolment (BMT may be an option once the patient completed the&#xD;
             study).&#xD;
&#xD;
          5. Not eligible for intensive chemotherapy;&#xD;
&#xD;
               1. Age ≥75 years Or&#xD;
&#xD;
               2. Age ≥18 years with at least one of the following comorbidities:&#xD;
&#xD;
             I. Significant heart or lung comorbidities, as reflected by at least one of the&#xD;
             following:&#xD;
&#xD;
               -  Left ventricular ejection fraction (LVEF) ≤50%&#xD;
&#xD;
               -  Lung diffusing capacity for carbon monoxide (DLCO) ≤65% of expected&#xD;
&#xD;
               -  Forced expiratory volume in 1 second (FEV1) ≤65% of expected II. Other&#xD;
                  comorbidity that the Investigator judges as incompatible with intensive&#xD;
                  chemotherapy, which must be documented&#xD;
&#xD;
          6. Creatinine clearance (estimated by the Modification of Diet in Renal Disease (MDRD)&#xD;
             equation or measured by 24 hours urine collection) ≥45 mL/min&#xD;
&#xD;
          7. Liver enzymes (aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT)&#xD;
             ≤2.5 times the upper limits of normal (ULN), unless attributed to leukemia (in AML&#xD;
             patients)&#xD;
&#xD;
          8. Total bilirubin ≤3 XULN unless due to Gilbert disease&#xD;
&#xD;
          9. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2&#xD;
&#xD;
         10. Women of reproductive potential must have a negative serum pregnancy test within 48&#xD;
             hours prior to the first day of any BST-236 treatment course&#xD;
&#xD;
         11. Women of reproductive potential must use two forms of effective birth control methods&#xD;
             starting from at least 1 month prior to BST-236 first dose and until 6 months&#xD;
             following the last BST-236 administration day (acceptable methods of birth control in&#xD;
             this study include: surgical sterilization, intrauterine devices, intrauterine&#xD;
             hormone-releasing system, long-acting injectable contraceptives, or vasectomized&#xD;
             partner (provided that partner is the sole sexual partner)&#xD;
&#xD;
         12. Male subjects must agree to refrain from unprotected sex unless vasectomized and from&#xD;
             sperm donation from initial study drug administration until 6 months following the&#xD;
             last dose of study drug&#xD;
&#xD;
         13. Subject must voluntarily sign and date an informed consent, approved by an Independent&#xD;
             Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of&#xD;
             any screening or study-specific procedures&#xD;
&#xD;
         14. Patient must be able to adhere to the study visit schedule and other protocol&#xD;
             requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients with any one of the exclusion criteria listed below are not eligible for the&#xD;
        study:&#xD;
&#xD;
          1. MDS or AML evolving from a pre-existing myeloproliferative neoplasm (MPN)&#xD;
&#xD;
          2. MDS/MPN including chronic myelomonocytic leukemia (CMML), atypical chronic myeloid&#xD;
             leukemia (CML), juvenile myelomonocytic leukemia (JMML) and unclassifiable MDS/MPN&#xD;
&#xD;
          3. Acute promyelocytic leukemia&#xD;
&#xD;
          4. Previous treatment for AML or MDS with drugs other than HMA or LDAC or combinations of&#xD;
             venetoclax with either HMA or LDAC&#xD;
&#xD;
          5. Previous allogeneic hematopoietic stem cell transplantation (HSCT) or solid organ&#xD;
             transplantation&#xD;
&#xD;
          6. Participation in a previous clinical trial involving use of an investigational drug&#xD;
             within 30 days or at least 5 half-lives of tested drug (whichever is shorter) of study&#xD;
             day 1&#xD;
&#xD;
          7. Peripheral White Blood Cell (WBC) count &gt;30,000/L in the 48 hours prior to first&#xD;
             BST-236 dose administration. Hydroxyurea administration or leukapheresis is permitted&#xD;
             to meet this criterion&#xD;
&#xD;
          8. Administration of HMA, LDAC, or venetoclax within 14 days prior to Study Day 1&#xD;
&#xD;
          9. Previous treatment with cytarabine at a dose higher than 20 mg/ m2/d&#xD;
&#xD;
         10. Uncontrolled systemic fungal, bacterial, or viral infection (defined as ongoing&#xD;
             signs/symptoms related to the infection without improvement despite appropriate&#xD;
             antibiotics or other treatment)&#xD;
&#xD;
         11. Any medical or surgical condition, presence of laboratory abnormalities or psychiatric&#xD;
             illness that may preclude safe and complete study participation based on the&#xD;
             Investigator's judgment&#xD;
&#xD;
         12. Diagnosis of malignant disease (other than AML) within the previous 12 months&#xD;
             (excluding basal cell carcinoma of the skin without complications, &quot;in-situ&quot;&#xD;
             carcinoma, or other local malignancy excised or irradiated with a high probability of&#xD;
             cure and not treated with systemic or topical chemotherapy)&#xD;
&#xD;
         13. Surgical procedure, excluding central venous catheter placement or other minor&#xD;
             procedures (e.g. skin biopsy) in the 14 days prior to first BST-236 dose&#xD;
             administration&#xD;
&#xD;
         14. History of allergic reactions attributed to compounds of similar chemical composition&#xD;
             as BST-236 and/or cytarabine&#xD;
&#xD;
         15. Life expectancy shorter than 3 months attributed to any known medical condition other&#xD;
             than AML/MDS&#xD;
&#xD;
         16. Known infection with Hepatitis B Virus (HBV) Hepatitis C Virus (HCV) or Human&#xD;
             Immunodeficiency Virus (HIV)&#xD;
&#xD;
         17. In 12 leads ECG, corrected QT interval (QTc)&gt;480msec or history of QT prolongation or&#xD;
             Torsades de pointes&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie Anne HOSPITAL, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Paoli Calmettes-Marseille</affiliation>
  </overall_official>
  <overall_official>
    <last_name>PIERRE FENAUX, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital St Louis-Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>FATIHA CHERMAT, Director</last_name>
    <phone>+33 (0)1 71 20 70 59</phone>
    <email>fatiha.chermat-ext@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>LAMYA AIT SI SELMI</last_name>
    <phone>+33 (0)1 71 20 70 55</phone>
    <email>lamya.aitsiselmi-ext@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Magalie JORIS, MD</last_name>
      <phone>+33 03 22 45 54 66</phone>
      <email>joris.magalie@chu-amiens.fr</email>
    </contact>
    <investigator>
      <last_name>Magalie JORIS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU d'Angers</name>
      <address>
        <city>Angers</city>
        <zip>49100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvain THEPOT, MD</last_name>
      <phone>+33 02 41 35 44 66</phone>
      <email>sylvain.thepot@chu-angers.fr</email>
    </contact>
    <investigator>
      <last_name>Sylvain THEPOT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Besançon - Hôpital Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ana BERCEANU, MD</last_name>
      <phone>+33 03 81 66 83 51</phone>
      <email>aberceanu@chu-besancon.fr</email>
    </contact>
    <investigator>
      <last_name>Ana BERCEANU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux Haut-Lévèque</name>
      <address>
        <city>Bordeaux</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sophie DIMICOLI-SALAZAR, MD</last_name>
      <phone>+33 05 57 65 65 11</phone>
      <email>sophie.dimicoli-salazar@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Sophie DIMICOLI-SALAZAR, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sophie PARK, Pr</last_name>
      <phone>+33 04 76 76 62 77</phone>
      <email>spark@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Sophie PARK, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Le Mans</name>
      <address>
        <city>Le Mans</city>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kamel LARIBI, MD</last_name>
      <phone>+33 02 43 43 43 61</phone>
      <email>klaribi@ch-lemans.fr</email>
    </contact>
    <investigator>
      <last_name>Kamel LARIBI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Limoges - Hôpital Dupuytren</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marie-Pierre GOURIN, MD</last_name>
      <phone>+33 05 55 05 66 42</phone>
      <email>marie-pierre.gourin@chu-limoges.fr</email>
    </contact>
    <investigator>
      <last_name>Marie-Pierre GOURIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marie-Anne HOSPITAL, MD</last_name>
      <phone>+33 04 91 22 37 54</phone>
      <email>hospitalm@ipc.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Marie-Anne HOSPITAL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nantes - Hôtel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alice GARNIER, MD</last_name>
      <phone>+33 02 40 08 32 71</phone>
      <email>alice.garnier@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Alice GARNIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nice - Hôpital Archet 1</name>
      <address>
        <city>Nice</city>
        <zip>06200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas CLUZEAU, Pr</last_name>
      <phone>+33 04 92 03 58 44</phone>
      <email>cluzeau.t@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>Thomas CLUZEAU, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre FENAUX, Pr</last_name>
      <phone>+ 33 01 71 20 70 22</phone>
      <email>pierre.fenaux@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre FENAUX, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jose Miguel TORREGROSA DIAZ, MD</last_name>
      <phone>+33 05 48 44 44 44</phone>
      <email>jose-miguel.torregrosa-diaz@chu-poitiers.fr</email>
    </contact>
    <investigator>
      <last_name>Jose Miguel TORREGROSA DIAZ, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stanislas NIMUBONA, MD</last_name>
      <phone>+33 02 99 28 95 21</phone>
      <email>stanislas.nimubona@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Stanislas NIMUBONA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie Lucien Neuwirth</name>
      <address>
        <city>Saint Priest-en-Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Caroline LEJEUNE, MD</last_name>
      <phone>+33 04 77 91 70 61</phone>
      <email>caroline.lejeune@icloire.fr</email>
    </contact>
    <investigator>
      <last_name>Caroline LEJEUNE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse - IUCT Oncopole</name>
      <address>
        <city>Toulouse</city>
        <zip>31100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Odile BEYNE-RAUZY, MD</last_name>
      <phone>+33 05 31 15 62 64</phone>
      <email>beynerauzy.odile@iuct-oncopole.fr</email>
    </contact>
    <investigator>
      <last_name>Odile BEYNE-RAUZY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 18, 2021</study_first_submitted>
  <study_first_submitted_qc>March 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2021</study_first_posted>
  <last_update_submitted>June 8, 2021</last_update_submitted>
  <last_update_submitted_qc>June 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

